Johannes F E Mann

14PUBLICATIONS
58CO-AUTHORS
Behavioural epidemiologyNephrology and urologyClinical nutritionCharacterisation of biological macromoleculesMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Mar 29, 2026
Acute eGFR Changes and Their Mediation of Albuminuria Reduction with Empagliflozin and Finerenone.

Rajiv Agarwal, Ricardo Correa-Rotter, Sankar D Navaneethan

|Feb 18, 2026
Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial.

Katherine R Tuttle, Johannes F E Mann, Manuel M Mayrdorfer

|Dec 11, 2025
Impact of Oral Semaglutide on Kidney Outcomes in People With Type 2 Diabetes: Results From the SOUL Randomized Trial.

Johannes F E Mann, Nikolaus Marx, John E Deanfield

|Nov 06, 2025
Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.

Amy Mottl, Charlie Scott, Jennifer B Green

|Mar 29, 2025
Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.

Matthew M Y Lee, Naveed Sattar, Rodica Pop-Busui

|Jun 24, 2024
Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial.

Johannes F E Mann, Peter Rossing, George Bakris

Pageof 3

Frequent Collaborators

6 joint publications

Peter Rossing

4 joint publications

Richard Pratley

3 joint publications

Janet B McGill

3 joint publications

Amy Mottl